Myostatin, also known as growth differentiation factor 8, affects muscle mass by reducing protein synthesis and muscle growth, thus preventing unwanted hypertrophy [3]
doi:10.1001/jama.2021.3004 Marso SP, Bain SC, Consoli A, et al
Adults with obesitya body mass index (BMI) of 30 or greateror those with a BMI of 27 to 29.9 with a weight-related medical condition such as high blood pressure or obstructive sleep apnea, could qualify for the medication
A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration
The dual GLP-1 and GIP receptor activation produces metabolic changes that show up relatively quickly in laboratory measurements and research endpoints